Literature DB >> 33460042

A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patients.

Sarah Bird1,2, Charlotte Pawlyn1,2, Susanna Nallamilli3, Priya Sriskandarajah1, Martin Kaiser1,2, Kwee Yong3, Rakesh Popat3, Neil Rabin3, Kevin Boyd1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33460042     DOI： 10.1111/bjh.17076

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

1.  A registry study of relapsed or refractory multiple myeloma pre-exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38-targeted monoclonal antibody therapy in England.

Authors:  Ahmed Elsada; Amy Zalin-Miller; Craig Knott; Leonidas Caravotas
Journal:  EJHaem       Date:  2021-06-10

2.  PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma.

Authors:  Reeder M Robinson; Ashton P Basar; Leticia Reyes; Ravyn M Duncan; Hong Li; Nathan G Dolloff
Journal:  Cancer Chemother Pharmacol       Date:  2022-04-05       Impact factor: 3.288

3.  Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort.

Authors:  Nadjoua Maouche; Bhuvan Kishore; Zara Bhatti; Supratik Basu; Farheen Karim; Sharadha Sundararaman; Freya Collings; Bing Tseu; Heather Leary; Noel Ryman; Udaya Reddy; Grant D Vallance; Jaimal Kothari; Karthik Ramasamy
Journal:  PLoS One       Date:  2022-07-07       Impact factor: 3.752
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.